Spots Global Cancer Trial Database for Phase I Platinum Based Chemotherapy Plus Indomethacin

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Phase I Platinum Based Chemotherapy Plus Indomethacin

Official Title: Phase I Study Evaluating Indomethacin in Combination With Platinum-based Chemotherapy

Study ID: NCT01719926

Conditions

Colorectal Neoplasms

Esophageal Neoplasms

Ovarian Neoplasms

Interventions

Indomethacin

Study Description

Brief Summary: Mesenchymal stem cells (MSCs) are present in the circulation of cancer patients, and are recruited to the stroma of both the primary tumor and metastasis. Recent preclinical research has shown that in response to platinum-based chemotherapy, MSCs secrete two specific platinum-induced fatty acids (PIFAs) which induce resistance to a broad spectrum of chemotherapies. The secreted PIFAs are the fatty acid oxo-heptadecatetraenoic acid (KHT) and the omega-3 fatty acid hexadecatetraenoic acid (16:4). These PIFAs are produced via the COX-1 pathway. COX inhibitors, including indomethacin. This phase 1 study explores the safety of combining indomethacin with platinum containing chemotherapy.

Detailed Description: